Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Neurotransmitters other than dopamine, including neuropeptides, could have important pathophysiologic and therapeutic roles in Parkinson's disease. Both Met-enkephalin, the main transmitter of the striatopallidal pathway, and dynorphin, one of the co-transmitters of the striatonigral pathway display complex anatomic and biochemical interactions with the basal ganglionic dopamine system. In this study, the cerebrospinal fluid content of a proenkephalin derivative, Met5 enkephalin-Arg6-Gly7-Leu8 (MERGL), was found in significantly low concentrations in parkinsonian patients following overnight withdrawal of all medications compared with control subjects, and failed to change after at least 16 h of steady-state, optimal doses of levodopa infusion intravenously. MERGL levels increased with advancing age among normal individuals but not among patients with Parkinson's disease. In contrast dynorphin A(1-8) levels were not different between the two study groups, did not change with levodopa therapy, and failed to correlate with age or any indices of disease progression. These observations, consistent with post-mortem studies on Parkinson brains and contrary to findings in animal models of Parkinsonism, suggest that abnormality of the enkephalin system in this disease is due to involvement of these striatal neurons in the primary pathologic process.
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
F
F
Baronti
K E
KE
Conant
M
M
Giuffra
T L
TL
Davis
G
G
Brughitta
M J
MJ
Iadarola
W H
WH
Berrettini
T N
TN
Chase
M M
MM
Mouradian
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004298:Dopamine / Q000378:metabolism*; D004399:Dynorphins / Q000134:cerebrospinal fluid; D004723:Endorphins / Q000378:metabolism*; D004744:Enkephalin, Methionine / Q000031:analogs & derivatives / Q000134:cerebrospinal fluid; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D007262:Infusions, Intravenous; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid
D004723:Endorphins; D010446:Peptide Fragments; D007980:Levodopa; D004744:Enkephalin, Methionine; D004399:Dynorphins; C026770:dynorphin (1-8); C033453:enkephalin-Met, Arg(6)-Gly(7)-Leu(8)-; D004298:Dopamine; D006719:Homovanillic Acid